N@N

Market Maker Surveillance Report. SIAF, SBAY, ACAD, BFSB, XOMA, PSDV, Losing Stocks With Lowest Price Friction For Monday, Dec

^{Published on 2010-12-27 19:00:51 - WOPRAI}
 

December 27, 2010 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 2587 companies with "abnormal" market making, 2844 companies with positive Friction Factors and 2644 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. SINO AGRO FOODS INC (OTC:SIAF), SUBAYE INC (NASDAQ:SBAY), ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD), BROOKLYN FEDERAL BANCORP INC (NASDAQ:BFSB), XOMA LTD (NASDAQ:XOMA), PSIVIDA CORP (NASDAQ:PSDV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     SIAF       $-0.125      -8.62%       103,700         44.39%       118,892         50.90%       -15,192         -1,215  
     SBAY       $-0.960      -10.40%      145,817         38.95%       198,570         53.04%       -52,753         -550    
     ACAD       $-0.140      -9.55%       1,241,826       43.89%       1,582,780       55.94%       -340,954        -24,354 
     BFSB       $-0.160      -11.34%      43,340          36.20%       76,400          63.80%       -33,060         -2,066  
     XOMA       $-1.020      -14.25%      8,301,773       45.20%       9,939,364       54.12%       -1,637,591      -16,055 
     PSDV       $-1.170      -18.40%      593,122         48.96%       608,743         50.25%       -15,621         -134    

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows PSDV with a dollar loss Monday of $-1.17000 and a Friction Factor of -134 shares. That means that it only took 134 more shares of selling than buying to move PSDV lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

SINO AGRO FOODS INC (OTC:SIAF) - Sino Agro Food, Inc., together with its subsidiaries, engages in developing, producing, and distributing agricultural products in the Peoples Republic of China. The company involves in selling fishery plants and equipment, managing fisheries, and marketing fish and fish products, as well as selling technology sub-licenses, which include A Power Technology, which is a fish growing system and technology; and provides fishery consulting services. It also engages in producing and selling fresh liquid milk; rearing and selling beef cattle; planting crops for the purpose of further processing into livestock feed; processing, packaging, and selling value added dairy products; and processing and selling livestock feed, as well as fertilizers. The company sells its organic dairy products under the brand name of YuanTianRan. In addition, it harvests the green flowers from the Hylocereous Undatus (HU) plants before they mature into fruits, as well as sells them as vegetables; and involves in drying, processing, and packaging the HU plants green flowers. The company was formerly known as A Power Agro Agriculture Development, Inc. and changed its name to Sino Agro Foods, Inc. in October 2007. Sino Agro Foods, Inc. was founded in 1974 and is based in Guangzhou, the Peoples Republic of China.

SUBAYE INC (NASDAQ:SBAY) - Subaye, Inc. provides video advertising and entertainment media services to small and medium sized enterprises in China. It operates in three segments: Online Membership Services, Entertainment Media, and Trade Services. The Online Membership Services segment provides online content and member services for commercial use. The Entertainment Media segment produces and places advertising solutions on behalf of its customers and invests in entertainment arts productions. The Trade Services segment provides domestic and international importing and exporting services to acquire and distribute goods within China or internationally. Subaye, Inc. offers SaaS online content management software to manage members online video and graphic showcases and operations within their Webshops at the online shopping mall and to maintain customer data. As of November 30, 2009, the company had 63,311 members. Its video database consisted of 72,126 profiles of corporate video showcases that offer venue for small to mid-size enterprises to advertise their products and services, and establish and enhance their corporate brands. The company was formerly known as MyStarU.com, Inc. and changed its name to Subaye, Inc. in October 2009. Subaye, Inc. was founded in 1997 and is headquartered in Guangzhou, the Peoples Republic of China.

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company is developing a portfolio of four product candidates, including pimavanserin, which is being developed for three separate neurological and psychiatric indications in collaboration with Biovail. These indications include Parkinsons disease psychosis that is in Phase III development; adjunctive therapy for schizophrenia, which is in Phase III planning; and Alzheimers disease psychosis, for which ACADIA is planning to initiate a Phase II feasibility study. The company also has other products under development, including a product candidate in Phase II development for chronic pain; and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, as well as a program in IND-track development in collaboration with Meiji Seika Kaisha. The products in ACADIAs pipeline emanate from discoveries made using its proprietary drug discovery platform. The company, formerly known as Receptor Technologies, Inc., was founded in 1993 and is headquartered in San Diego, California.

BROOKLYN FEDERAL BANCORP INC (NASDAQ:BFSB) - Brooklyn Federal Bancorp, Inc. operates as the holding company for Brooklyn Federal Savings Bank, a federally chartered savings bank that provides various banking products and services in Brooklyn, Nassau, and Suffolk, New York. It primarily engages in generating deposits and originating loans. The companys deposit products include demand deposits consisting of non-interest bearing checking accounts, negotiable order of withdrawal accounts, money market accounts, passbook savings and club accounts, and fixed-term certificates of deposit. Its loan portfolio principally consists of mortgage loans secured by one- to four-family residential real estate, multi-family real estate, and commercial real estate loans, as well as construction loans, land loans, and various consumer loans and home equity loans. The company also involves in selling insurance and fixed annuity products; and acquiring, holding, and investing in certain real estate-related loans and other assets. As of September 30, 2009, it provided its services through its main office and five branch offices located in the state of New York. The company was founded in 1887 and is headquartered in Brooklyn, New York. Brooklyn Federal Bancorp, Inc. is a subsidiary of BFS Bancorp, MHC.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

PSIVIDA CORP (NASDAQ:PSDV) - pSivida Corp., together with its subsidiaries, develops drug delivery products in the healthcare sector. It develops products utilizing its proprietary technologies, including Durasert, BioSilicon, CODRUG, and Medidur. The companys products include Retisert for the treatment of posterior uveitis; and Vitrasert for the treatment of AIDS-related cytomegalovirus retinitis. Its products also include Iluvien, a Phase III clinical trial product for the treatment of diabetic macular edema; and Durasert and Iluvien, which are under pre-clinical trials to treat retinitis pigmentosa and age-related macular degeneration. In addition, pSivida Corp. owns the rights to develop and commercialize a modified form of silicon, known as BioSilicon, which has therapeutic applications for treatment of cancer. Its lead BioSilicon product is BrachySil, which is in Phase II clinical trial for the treatment of pancreatic cancer. The company primarily operates in the United Kingdom and the United States. It has strategic collaborations with Chiron Vision Corporation; Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is based in Watertown, Massachusetts.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net